2024-10-19 - Analysis Report
## Pfizer Inc. (PFE) Stock Analysis Report

**1. Performance Comparison:**

Pfizer Inc. (PFE) is a pharmaceutical company that develops and manufactures medicines and vaccines.  

As of today, PFE has a cumulative return of **-11.55%**, significantly underperforming the S&P 500 (VOO) with a cumulative return of **136.97%**. The relative divergence currently sits at **-148.52**, indicating that PFE has underperformed VOO by a substantial margin. This is the lowest point in the historical range, placing PFE at the 0.7 percentile of historical performance compared to VOO.

**2. Recent Price Movements:**

PFE's closing price is **$29.27**. The stock has been relatively stable in the short term, with its 5-day moving average at **$29.32** and 20-day moving average at **$29.14**. The 60-day moving average stands at **$29.25**, indicating some potential for a short-term rebound.

**3. Technical Indicators:**

- **RSI (50.93):** The RSI suggests that PFE is trading in a neutral territory, neither overbought nor oversold.
- **PPO (0.14):**  The PPO is slightly positive, implying potential for further growth.
- **Delta_Previous_Relative_Divergence (-):** This suggests a recent short-term downward trend in relative performance compared to VOO.
- **Expected_Return (0.0%):**  The expected return is currently 0%, suggesting that over the next five years, PFE is projected to match the market performance of VOO.

**4. Recent Earnings and Outlook:**

Pfizer's recent earnings performance has been mixed.

| Date       | EPS    | Expected EPS |
|------------|--------|---------------|
| 2024-07-30 | 0.6    | 0.458         |
| 2024-05-01 | 0.82   | 0.516         |
| 2024-01-30 | 0.1    | -0.19         |
| 2023-10-31 | -0.17  | -0.32         |
| 2023-08-01 | 0.67   | 0.56          |

The most recent earnings report for Q2 2024 shows that PFE beat analyst estimates with an EPS of **0.6**, exceeding the expected EPS of **0.458**.

**5. News and Recent Issues:**

According to FINBOLD, the market outlook for PFE is positive with a "Buy" rating from analysts.  Key performance highlights include Pfizer's continued focus on developing innovative medicines and its strong financial performance.

Recent news and events that may impact PFE include:

* The ongoing impact of the COVID-19 pandemic and its effect on global demand for Pfizer's vaccines.
* Regulatory approval processes for new drugs and treatments.
* Competition from other pharmaceutical companies.

**6. Overall Analysis:**

Despite the recent earnings beat, PFE's stock performance has significantly lagged behind the S&P 500 (VOO). Technical indicators suggest a neutral outlook, with some potential for a short-term rebound. The expected return is currently 0%, aligning with the performance of the broad market. While PFE has a strong track record of innovation and revenue generation, its performance may be susceptible to volatility due to the ongoing impact of the COVID-19 pandemic and intense competition within the pharmaceutical industry.

**7. Recommendation:**

While PFE's recent earnings beat and positive analyst outlook are encouraging, its historical underperformance compared to the market and potential volatility make it a relatively risky investment. Investors considering PFE should carefully weigh its potential for growth against its risks and consider a long-term perspective for potential returns. 
